74927-05-2

Upstream product

• 74931-59-2 1-isopropyl-2-methoxymethyloxybenzene 
• 68-12-2 N,N-dimethyl-formamide 
• 67372-96-7 3-isopropylsalicylaldehyde 
• 107-30-2 chloromethyl methyl ether 
• 88-69-7 2-(1-methylethyl)phenol 

Downstream Products

• 1160758-65-5 C₁₂H₁₈O₃ 
• 1433062-86-2 C₁₁H₁₆O₂ 
• 1433062-80-6 C₁₃H₂₀O₃ 
• 1433062-92-0 C₁₆H₂₄O₄ 
• 1433062-98-6 C₂₂H₃₈O₄Si 
• 1441180-58-0 3-ethoxy-1-(3-isopropyl-2-(methoxymethoxy)phenyl)prop-2-yn-1-ol 
• 873011-45-1 1-(dimethoxymethyl)-3-isopropyl-2-(methoxymethoxy)benzene 
• 74927-07-4 2-cyclopropyl-6-isopropylphenyl methoxymethyl ether 
• 74926-96-8 2-cyclopropyl-6-isopropylphenol 
• 67372-96-7 3-isopropylsalicylaldehyde 
• 74927-06-3 cis-3-isopropyl-2-methoxymethoxycinnamaldehyde 
• 74927-06-3 trans-3-isopropyl-2-methoxymethoxycinnamaldehyde 

Relevant academic research and scientific papers

Asymmetric induction via short-lived chiral enolates with a chiral C-O axis

A novel method has been developed for the asymmetric cyclization of alkyl aryl ethers. The reactions were assumed to proceed via short-lived chiral enolate intermediates with a chiral C-O axis to give cyclic ethers with tetrasubstituted carbon in up to 99% ee. The half-life of racemization of the chiral enolate intermediate was roughly estimated to be ～1 s at -78 C.

Expeditious synthesis of benzopyrans via lewis acid-catalyzed C-H functionalization: Remarkable enhancement of reactivity by an ortho substituent

An expeditious construction of a benzopyran skeleton via Lewis acid-catalyzed C-H functionalization was achieved. In this process, a [1,5] hydride shift and 6-endo cyclization successively occurred to give benzopyrans. The presence of substituents ortho to the alkoxy group significantly enhanced the reactivity, affording the desired compounds in excellent chemical yields with short reaction times.

BENZENE COMPOUND HAVING 2 OR MORE SUBSTITUENTS

A superior LXR modulator is provided. A compound represented by the general formula (I): [wherein R1: -COR9 (wherein R9: alkyl, optionally substituted alkoxy or optionally substituted amino); R2: H, OH, alkoxy, optionally substituted amino, etc.; R3: H, optionally substituted alkyl, cycloalkyl, optionally substituted alkoxy, optionally substituted amino, halogeno, etc.; R4 and R5: H, optionally substituted alkyl, halogeno, etc.; R6 and R7: H, alkyl; R8: -X2R10 [wherein R10: -COR11 (wherein R11 : OH, optionally substituted alkoxy, optionally substituted amino, etc.), -SO2R12 (wherein R12: optionally substituted alkyl, optionally substituted amino, etc.), tetrazol-5-yl, etc.; X2: single bond, optionally substituted alkylene, etc.]; X1: -NH-, -O-, -S-, etc.; Y1: optionally substituted phenyl, optionally substituted 5- to 6-membered aromatic heterocyclyl; Y2: optionally substituted aryl, optionally substituted heterocyclyl, etc.] and the like is provided.

Stereoselective ring-opening polymerization of a racemic lactide by using achiral salen- and homosalen-aluminum complexes

Highly isotactic polylactide or poly(lactic acid) is synthesized in a ring-opening polymerization (ROP) of racemic lactide with achiral salen- and homosalen-aluminum complexes (salenH2 = N,N′-bis(salicylidene) ethylene-1,2-diamine; homosalenH2 = N,N′-bis(salicylidene) trimethylene-1,3-diamine). A systematic exploration of ligands demonstrates the importance of the steric influence of the Schiff base moiety on the degree of isotacticity and the backbone for high activity. The complexes prepared in situ are pure enough to apply to the polymerizations without purification. The crystal structures of the key complexes are elucidated by X-ray diffraction, which confirms that they are chiral. However. analysis of the 1H and 13C NMR spec tra unambiguously demonstrates that their conformations are so flexible that the chiral environment of the complexes cannot be maintained in solution at 25°C and that the complexes are achiral under the polymerization conditions. The flexibility of the back-bone in the propagation steps is also documented. Hence, the isotacticity of the polymer occurs due to a chain-end control mechanism. The highest reactivity in the present system is obtained with the homosalen ligand with 2.2-dimethyl substituents in the backbone (ArCH=NCH2CMe2CH2N=CHAr), whereas tBuMe2Si substituents at the 3-positions of the salicylidene moieties lead to the highest selectivity (Pmeso,= 0.98; T m = 210°C). The ratio of the rate constants in the ROPs of racemic lactide and L-lactide is found to correlate with the stereoselectivity in the present system. The complex can be utilized in bulk polymerization, which is the most attractive in industry, although with some loss of stereoselectivity at high temperature, and the afforded polymer shows a higher melting temperature (Pmeso = 0.92, Tm up to 189°C) than that of homochiral poly(L-lactide) (Tm = 162-180°C). The "livingness" of the bulk polymerization at 130°C is maintained even at a high conversion (97-98%) and for an extended polymerization time (1-2 h).

ASYMMETRIC REACTION CATALYST AND PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE COMPOUNDS WITH THE SAME

An asymmetric reaction catalyst is obtained by mixing a pentavalent niobium compound and an optically active triol or tetraol having a binaphthol structure of R or S configuration, and the triol is represented by the following formula: (wherein, Y is divalent hydrocarbon and R 1 is a hydrogen atom, a halogen atom, a trifluoromethyl group, or an alkyl group or alkoxy group having at most 4 carbons).

A novel dinuclear chiral niobium complex for Lewis acid catalyzed enantioselective reactions: Design of a tridentate ligand and elucidation of the catalyst structure

Two's company: By using a novel chiral ligand a dinuclear chiral niobium catalyst for highly enantioselective Mannich-type reactions was developed. Tridentate binol derivatives provide excellent asymmetric environments around the niobium atom, and the Man

Synthesis, Biological Evaluation, and Preliminary Structure-Activity Considerations of a Series of Alkylphenols as Intravenous Anesthetic Agents

Following our discovery of the intravenous (iv) anesthetic activity of 2,6-diethylphenol in mice, a series of alkylphenols was examined in this species and the most active analogues were further evaluated in rabbits.The synthesis of compounds which were not commercially available was accomplished by adaptations of standard ortho-alkylation procedures for phenols.Structure-activity relationships were found to be complex, but, in general, potency and kinetics appeared to be a function of both the lipophilic character and the degree of steric hindrance exerted by ortho substituents.The most interesting compounds were found in the 2,6-dialkyl series, and the greatest potency was associated with 2,6-di-sec-alkyl substitution.In particular, 2,6-diisopropylphenol (ICI 35868) emerged as a candidate for further development and has subsequently been shown to be an effective iv anesthetic agent in man.